Intracranial  ||| S:0 E:13 ||| JJ
stents  ||| S:13 E:20 ||| NN
for  ||| S:20 E:24 ||| IN
treatment  ||| S:24 E:34 ||| NN
of  ||| S:34 E:37 ||| IN
acute  ||| S:37 E:43 ||| JJ
ischemic  ||| S:43 E:52 ||| JJ
stroke ||| S:52 E:58 ||| NN
:  ||| S:58 E:60 ||| :
evolution  ||| S:60 E:70 ||| NN
and  ||| S:70 E:74 ||| CC
current  ||| S:74 E:82 ||| JJ
status  ||| S:82 E:89 ||| NN
Intravascular  ||| S:89 E:103 ||| NNP
stents  ||| S:103 E:110 ||| NNS
have  ||| S:110 E:115 ||| VBP
been  ||| S:115 E:120 ||| VBN
applied  ||| S:120 E:128 ||| VBN
to  ||| S:128 E:131 ||| TO
treat  ||| S:131 E:137 ||| VB
a  ||| S:137 E:139 ||| DT
variety  ||| S:139 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
pathophysiologic  ||| S:150 E:167 ||| JJ
conditions ||| S:167 E:177 ||| NNS
.  ||| S:177 E:179 ||| .
With  ||| S:179 E:184 ||| IN
advances  ||| S:184 E:193 ||| NNS
in  ||| S:193 E:196 ||| IN
stent  ||| S:196 E:202 ||| JJ
design  ||| S:202 E:209 ||| NN
and  ||| S:209 E:213 ||| CC
delivery ||| S:213 E:221 ||| NN
,  ||| S:221 E:223 ||| ,
stenting  ||| S:223 E:232 ||| NN
has  ||| S:232 E:236 ||| VBZ
become  ||| S:236 E:243 ||| VBN
a  ||| S:243 E:245 ||| DT
viable  ||| S:245 E:252 ||| JJ
treatment  ||| S:252 E:262 ||| NN
option  ||| S:262 E:269 ||| NN
in  ||| S:269 E:272 ||| IN
neurovascular  ||| S:272 E:286 ||| JJ
disease ||| S:286 E:293 ||| NN
.  ||| S:293 E:295 ||| .
Recently ||| S:295 E:303 ||| RB
,  ||| S:303 E:305 ||| ,
intracranial  ||| S:305 E:318 ||| FW
arterial  ||| S:318 E:327 ||| FW
stenting  ||| S:327 E:336 ||| FW
has  ||| S:336 E:340 ||| VBZ
received  ||| S:340 E:349 ||| VBN
increasing  ||| S:349 E:360 ||| VBG
interest  ||| S:360 E:369 ||| NN
as  ||| S:369 E:372 ||| IN
a  ||| S:372 E:374 ||| DT
modality  ||| S:374 E:383 ||| NN
to  ||| S:383 E:386 ||| TO
rapidly  ||| S:386 E:394 ||| RB
and  ||| S:394 E:398 ||| CC
effectively  ||| S:398 E:410 ||| RB
recanalize  ||| S:410 E:421 ||| JJ
affected  ||| S:421 E:430 ||| JJ
vessels  ||| S:430 E:438 ||| NNS
in  ||| S:438 E:441 ||| IN
the  ||| S:441 E:445 ||| DT
setting  ||| S:445 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
acute  ||| S:456 E:462 ||| JJ
ischemic  ||| S:462 E:471 ||| JJ
stroke ||| S:471 E:477 ||| NN
.  ||| S:477 E:479 ||| .
To  ||| S:479 E:482 ||| TO
examine  ||| S:482 E:490 ||| VB
the  ||| S:490 E:494 ||| DT
potential  ||| S:494 E:504 ||| NN
of  ||| S:504 E:507 ||| IN
stenting  ||| S:507 E:516 ||| JJ
procedures  ||| S:516 E:527 ||| NNS
for  ||| S:527 E:531 ||| IN
stroke ||| S:531 E:537 ||| NN
,  ||| S:537 E:539 ||| ,
we  ||| S:539 E:542 ||| PRP
compiled  ||| S:542 E:551 ||| VBN
and  ||| S:551 E:555 ||| CC
analyzed  ||| S:555 E:564 ||| VBD
relevant  ||| S:564 E:573 ||| JJ
experimental  ||| S:573 E:586 ||| JJ
and  ||| S:586 E:590 ||| CC
clinical  ||| S:590 E:599 ||| JJ
studies  ||| S:599 E:607 ||| NNS
in  ||| S:607 E:610 ||| IN
the  ||| S:610 E:614 ||| DT
available  ||| S:614 E:624 ||| JJ
databases ||| S:624 E:633 ||| NN
.  ||| S:633 E:635 ||| .
Our  ||| S:635 E:639 ||| PRP$
resulting  ||| S:639 E:649 ||| JJ
discussion  ||| S:649 E:660 ||| NN
covers  ||| S:660 E:667 ||| VBZ
the  ||| S:667 E:671 ||| DT
brief  ||| S:671 E:677 ||| JJ
history  ||| S:677 E:685 ||| NN
of  ||| S:685 E:688 ||| IN
stents ||| S:688 E:694 ||| NN
,  ||| S:694 E:696 ||| ,
from  ||| S:696 E:701 ||| IN
their  ||| S:701 E:707 ||| PRP$
initial  ||| S:707 E:715 ||| JJ
inception  ||| S:715 E:725 ||| NN
in  ||| S:725 E:728 ||| IN
the  ||| S:728 E:732 ||| DT
1960s ||| S:732 E:737 ||| NNS
,  ||| S:737 E:739 ||| ,
to  ||| S:739 E:742 ||| TO
the  ||| S:742 E:746 ||| DT
developments  ||| S:746 E:759 ||| NNS
of  ||| S:759 E:762 ||| IN
interventional  ||| S:762 E:777 ||| JJ
cardiology ||| S:777 E:787 ||| NN
,  ||| S:787 E:789 ||| ,
and  ||| S:789 E:793 ||| CC
finally  ||| S:793 E:801 ||| RB
to  ||| S:801 E:804 ||| TO
the  ||| S:804 E:808 ||| DT
treatment  ||| S:808 E:818 ||| NN
of  ||| S:818 E:821 ||| IN
acute  ||| S:821 E:827 ||| JJ
occlusions  ||| S:827 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
the  ||| S:841 E:845 ||| DT
neurovasculature ||| S:845 E:861 ||| NN
.  ||| S:861 E:863 ||| .
We  ||| S:863 E:866 ||| PRP
also  ||| S:866 E:871 ||| RB
detail  ||| S:871 E:878 ||| JJ
technological  ||| S:878 E:892 ||| JJ
advances  ||| S:892 E:901 ||| NNS
that  ||| S:901 E:906 ||| WDT
have  ||| S:906 E:911 ||| VBP
improved  ||| S:911 E:920 ||| VBN
stent  ||| S:920 E:926 ||| JJ
delivery  ||| S:926 E:935 ||| NN
to  ||| S:935 E:938 ||| TO
intracranial  ||| S:938 E:951 ||| VB
arteries  ||| S:951 E:960 ||| NNS
and  ||| S:960 E:964 ||| CC
review  ||| S:964 E:971 ||| VB
the  ||| S:971 E:975 ||| DT
several  ||| S:975 E:983 ||| JJ
clinical  ||| S:983 E:992 ||| JJ
studies  ||| S:992 E:1000 ||| NNS
that  ||| S:1000 E:1005 ||| WDT
feature  ||| S:1005 E:1013 ||| VBP
stenting  ||| S:1013 E:1022 ||| VBN
for  ||| S:1022 E:1026 ||| IN
the  ||| S:1026 E:1030 ||| DT
treatment  ||| S:1030 E:1040 ||| NN
of  ||| S:1040 E:1043 ||| IN
acute  ||| S:1043 E:1049 ||| JJ
ischemic  ||| S:1049 E:1058 ||| JJ
stroke ||| S:1058 E:1064 ||| NN
.  ||| S:1064 E:1066 ||| .
Numerous  ||| S:1066 E:1075 ||| JJ
clinical  ||| S:1075 E:1084 ||| JJ
studies  ||| S:1084 E:1092 ||| NNS
have  ||| S:1092 E:1097 ||| VBP
revealed  ||| S:1097 E:1106 ||| VBN
that  ||| S:1106 E:1111 ||| IN
stents  ||| S:1111 E:1118 ||| NNS
are  ||| S:1118 E:1122 ||| VBP
a  ||| S:1122 E:1124 ||| DT
quick  ||| S:1124 E:1130 ||| JJ
and  ||| S:1130 E:1134 ||| CC
efficacious  ||| S:1134 E:1146 ||| JJ
endovascular  ||| S:1146 E:1159 ||| JJ
tool  ||| S:1159 E:1164 ||| NN
for  ||| S:1164 E:1168 ||| IN
acute  ||| S:1168 E:1174 ||| JJ
ischemic  ||| S:1174 E:1183 ||| JJ
stroke  ||| S:1183 E:1190 ||| NN
treatment ||| S:1190 E:1199 ||| NN
.  ||| S:1199 E:1201 ||| .
It  ||| S:1201 E:1204 ||| PRP
appears  ||| S:1204 E:1212 ||| VBZ
likely  ||| S:1212 E:1219 ||| RB
that  ||| S:1219 E:1224 ||| IN
issues  ||| S:1224 E:1231 ||| NNS
regarding  ||| S:1231 E:1241 ||| VBG
design ||| S:1241 E:1247 ||| NN
,  ||| S:1247 E:1249 ||| ,
safety ||| S:1249 E:1255 ||| NN
,  ||| S:1255 E:1257 ||| ,
and  ||| S:1257 E:1261 ||| CC
feasibility  ||| S:1261 E:1273 ||| NN
of  ||| S:1273 E:1276 ||| IN
stent-based  ||| S:1276 E:1288 ||| JJ
devices  ||| S:1288 E:1296 ||| NNS
will  ||| S:1296 E:1301 ||| MD
experience  ||| S:1301 E:1312 ||| VB
further  ||| S:1312 E:1320 ||| JJ
improvement  ||| S:1320 E:1332 ||| NN
and  ||| S:1332 E:1336 ||| CC
refinement ||| S:1336 E:1346 ||| NN
,  ||| S:1346 E:1348 ||| ,
and  ||| S:1348 E:1352 ||| CC
from  ||| S:1352 E:1357 ||| IN
fruitful  ||| S:1357 E:1366 ||| JJ
criticism  ||| S:1366 E:1376 ||| NN
of  ||| S:1376 E:1379 ||| IN
existing  ||| S:1379 E:1388 ||| VBG
technologies  ||| S:1388 E:1401 ||| NNS
and  ||| S:1401 E:1405 ||| CC
techniques ||| S:1405 E:1415 ||| NNS
,  ||| S:1415 E:1417 ||| ,
along  ||| S:1417 E:1423 ||| RB
with  ||| S:1423 E:1428 ||| IN
lessons  ||| S:1428 E:1436 ||| NNS
from  ||| S:1436 E:1441 ||| IN
past  ||| S:1441 E:1446 ||| JJ
mistakes ||| S:1446 E:1454 ||| NNS
,  ||| S:1454 E:1456 ||| ,
will  ||| S:1456 E:1461 ||| MD
arise  ||| S:1461 E:1467 ||| VB
safer  ||| S:1467 E:1473 ||| JJR
and  ||| S:1473 E:1477 ||| CC
more  ||| S:1477 E:1482 ||| RBR
effective  ||| S:1482 E:1492 ||| JJ
devices ||| S:1492 E:1499 ||| NNS
.  ||| S:1499 E:1501 ||| .
